DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Last trade$82.17
Day change+$0.56 (+0.69%)
Day range$80.06 – $84.01
Volume1,540,997
Market cap$30.44B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$30.44B
Price / earnings
30.71×
Price / book
12×
Price / sales
5.96×
EV / sales
6.02×
EV / EBITDA
20.5×
Profitability
Earnings per share
$2.66
Return on assets
15.88%
Return on equity
39.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.49×
Current ratio
1.74×
Quick ratio
1.4×
Cash ratio
0.43×
Cash flow
Price / cash flow
21.52×
Price / free cash flow
27.71×
Free cash flow
$1.1B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DXCM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.34B
$1.31B
$1.19B
$1.26B
$1.21B
$1.16B
$1.04B
$1.11B
Cost of revenue
$480.1M
$478.4M
$441.6M
$466.9M
$477.9M
$468.3M
$447M
$457.7M
Gross profit
$864.4M
$830M
$750.3M
$792.7M
$731.4M
$688.8M
$589M
$655.8M
Selling, general and administrative
$375.6M
$358.7M
$349.7M
$321.5M
$331.4M
$328M
$310.1M
$327.4M
Research and development
$161.6M
$153M
$145.3M
$148.2M
$157.5M
$148.2M
$145.2M
$139.5M
Total operating expenses
$537.2M
$511.7M
$495M
$469.7M
$488.9M
$476.2M
$455.3M
$466.9M
Operating income
$327.2M
$318.3M
$255.3M
$323M
$242.5M
$212.6M
$133.7M
$188.9M
Interest expense
$0
-$3M
$0
$0
$0
-$4.7M
$0
$0
Income before taxes
$334.7M
$317.5M
$269.5M
$340.7M
$352.3M
$241.1M
$154.3M
$211.3M
Income taxes
$59.6M
$68.4M
$70M
$73.4M
$68.5M
$61.3M
$48.9M
$59.6M
Net income
$275.1M
$249.1M
$199.5M
$267.3M
$283.8M
$179.8M
$105.4M
$151.7M
Net income attributable to common shareholders
$275.1M
$249.1M
$199.5M
$267.3M
$283.8M
$179.8M
$105.4M
$151.7M
EBITDA
$401.7M
$386.5M
$322.4M
$388.2M
$306.1M
$275.6M
$193.7M
$246.7M
Basic earnings per share
$0.73
$0.65
$0.52
$0.69
$0.73
$0.46
$0.27
$0.39
Diluted earnings per share
$0.72
$0.64
$0.51
$0.67
$0.70
$0.45
$0.27
$0.37
Recent news
Company coverage with links to the original publishers.
DexCom is well-positioned for growth driven by G7 15 Day adoption, international expansion, and manufacturing efficiencies that expanded Q3 gross margins to 65.1%. However, the company faces headwinds from PBM formulary risks, Ireland facility ramp-up costs, and rising R&D spending on G8 development. The stock has gained 22.6% year-to-date and maintains a Zacks Rank #3 (Hold) rating with improving 2026 earnings estimates.
DexCom announced the November launch of its G7 15 Day Continuous Glucose Monitoring system in Canada, offering up to 15.5 days of sensor wear with 8.0% MARD accuracy. The system features waterproof sensors, Apple Watch connectivity, and will be supported by public and private reimbursement coverage. DXCM stock gained 7.8% following the announcement and has risen 27.7% year-to-date.
India's continuous glucose monitoring market is projected to grow at a CAGR of 11.90% from 2027-2032, reaching USD 452.9 million by 2032. The market expansion is driven by growing adoption of sensor-based monitoring, digital healthcare integration, and expanding diabetes management programs. However, high device costs and limited reimbursement coverage remain barriers to wider adoption.
DexCom (DXCM) reported Q3 2026 adjusted EPS of 73 cents, beating estimates by 10.6%, with revenues growing 11.2% to $1.34B. U.S. revenues rose 13.8% while adjusted gross margin expanded 380 basis points to 65.1%. The company raised its 2026 revenue outlook to $5.20-$5.25B and authorized an additional $1B share buyback. International growth moderated to 4.8% due to prior-year reimbursement comparisons, but management expects recovery in early 2027.
DexCom is expected to report Q3 2026 revenues of $1.32 billion (up 9.4% YoY) and EPS of 66 cents (up 8.2% YoY) on October 29. Growth is supported by G7 15 Day adoption, strong new-patient starts, and broader reimbursement coverage, though the company faces headwinds from tougher international comparisons, forex pressures, and manufacturing costs. An earnings beat is not predicted despite positive fundamentals.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.